Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a "sensitive" relapse.

Trial Profile

Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a "sensitive" relapse.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2015 Results (n=9), published in the European Journal of Cancer.
    • 14 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Additional trial identifier NCT00953459, CDR0000639063, EU-20910 identified and inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top